Supplement: Many Happy Returns

Many Happy Returns By Charles Q. Choi Cephalon marks its 20th year RELATED ARTICLES Successful Strategies Margaret Foti: Devoted to cancer research The Launch and the Exit Entrepreneurs Boldly Break New Ground Mark Tykocinski: Open doors lead a scientist to his calling Shire Pharmaceuticals: A Study in Exponential Growth Creative Collaboration Cephalon, the leading independent biotechnology firm in Pennsylvania and the Greater Philadelphia region

Charles Q. Choi
Jan 1, 2008
Many Happy Returns
By Charles Q. Choi
Cephalon marks its 20th year

Cephalon, the leading independent biotechnology firm in Pennsylvania and the Greater Philadelphia region, has seen its fair share of rocky times in the last two decades. However, as the $5 billion market cap company celebrates its 20th anniversary, it stands in a far better position than it has ever been.

"Over the last 20 years we have used our keen eye for identifying opportunities, our research ingenuity, and sheer perseverance to grow from a startup biotech company to one of the top ten biotech companies in the world," says Frank Baldino, Jr., chairperson and CEO of Cephalon.

Baldino grew...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?